Synthesis and in Vitro Evaluation of Inhibitors of Intestinal Cholesterol Absorption
作者:Lisbet Kværnø,、Moritz Werder、Helmut Hauser、Erick M. Carreira
DOI:10.1021/jm050422p
日期:2005.9.1
We have utilized our recently developed in vitro assay to address two key questions in the design of small-molecule cholesterol absorption inhibitors using ezetimibe, the only drug yet approved for the inhibition of cholesterol absorption in the small intestine, as a starting point: (1) the role of glycosylation and (2) the importance of the beta-lactam scaffold of ezetimibe for inhibitory activity
我们已经利用我们最近开发的体外测定法来解决使用依泽替米贝设计小分子胆固醇吸收抑制剂的两个关键问题,依泽替米贝是唯一尚未批准的抑制小肠胆固醇吸收的药物,作为出发点:(1 )糖基化的作用,以及(2)依泽替米贝的β-内酰胺支架对于抑制活性的重要性。合成了多种依泽替米贝的不可水解酚类糖苷,并使用刷状缘膜囊泡测定法证明是胆固醇吸收的活性抑制剂。类似的氮杂环丁烷提供了体外使用各种抑制剂的途径,这表明依泽替米贝的β-内酰胺仅用作适当地定位所需取代基的环骨架。